ImmunoGen cancer drug development halted
Shares of ImmunoGen Inc fell 46 per cent after partner GlaxoSmithKline Plc, halted development of their experimental cancer drug. ImmunoGen which is based in Cambridge, Massachusetts, is working to
Shares of ImmunoGen Inc fell 46 per cent after partner GlaxoSmithKline Plc, halted development of their experimental cancer drug. ImmunoGen which is based in Cambridge, Massachusetts, is working to